Is Mar­tin Shkre­li blog­ging from prison?

Say what you will about Mar­tin Shkre­li, but the guy ap­pears to have a re­lent­less re­silience to be heard. A few months in­to his prison sen­tence at Fort Dix, Shkre­li might be blog­ging from his cell.

That’s ac­cord­ing to ac­tiv­i­ty on this site — mar­tin­shkre­ — which saw its first en­try post­ed yes­ter­day. Al­though it’s still un­clear if the blog is gen­uine, the first post was writ­ten in Shkre­li’s now-fa­mil­iar wry voice and style. He shares his per­son­al con­tact in­for­ma­tion, in­clud­ing an email ad­dress you can send ques­tions to. His peo­ple will print the emails and “snail mail” them to Shkre­li at the cor­rec­tion­al fa­cil­i­ty, the post says.

I’ve reached out to Fort Dix, the prison where Shkre­li is cur­rent­ly serv­ing his 7-year sen­tence for se­cu­ri­ties fraud, to see if Shkre­li can ac­tu­al­ly post blogs while in­car­cer­at­ed. What ac­cess does he have to the in­ter­net? In what cir­cum­stances would the fa­cil­i­ty in­ter­fere with his blog­ging? The in­sti­tu­tion took my call, but said it need­ed time to re­spond. I’m still wait­ing to hear back.

If the blog is in­deed gen­uine, it seems Shkre­li is de­ter­mined to share his thoughts on in­dus­try mat­ters. The first sec­tion of his first en­try is com­men­tary on bio stocks and in­dus­try news, with mus­ings like the one be­low:

No­var­tis’ much-telegraphed sale of Al­con and the con­tin­ued im­plo­sion of GE re­minds us con­glom­er­ates are more out of fash­ion than prob­a­bly at any point in the his­to­ry of busi­ness. This flies in the face of me­chan­i­cal log­ic, but prac­ti­cal­ly makes sense. Find­ing good man­agers is hard (I’ve maybe found a very small hand­ful of de­cent man­agers out of close to 1000 I’ve em­ployed over the years) and con­glom­er­ates can on­ly work if you have an en­gaged CEO (about 5% of CEOs) and en­gaged man­agers (less than 5%? less than 10%?), which prob­a­bil­i­ty tells you is far low­er.

Then he out­lines sci­en­tif­ic pa­pers he’s read from prison and adds notes on what he thinks about each. Last, he ded­i­cates a few para­graphs to his per­son­al life.

“I have around 38 months to go as­sum­ing no suc­cess on an ap­peal,” he wrote. “I spend most of my team [sic] read­ing. A news­pa­per mis­re­port­ed that I’m ‘buff’. This is not the case.”

He al­so writes that news out­lets have mis­re­port­ed facts about his as­sets.

“Oh, the Wu-Tang al­bum is still in my pos­ses­sion,” he wrote. “As are all of my as­sets.”

News writ­ers re­port­ed back in March that US Dis­trict Judge Kiyo Mat­sumo­to or­dered Shkre­li to for­feit $7.36 mil­lion. But that or­der got stayed — as we re­port­ed — pend­ing Shkre­li’s ap­peal, which could take a year or so to wrap up.

The news of Shkre­li’s blog was first not­ed by Christie Smythe, a le­gal jour­nal­ist who’s writ­ing a book about Shkre­li. Fol­low the con­ver­sa­tion via this tweet, and we’ll up­date this sto­ry once Fort Dix gets back to us:

Im­age: Mar­tin Shkre­li. SHUT­TER­STOCK

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right after jumping on Michael Milken’s FasterCures board on Monday, the newly departed FDA commissioner is back today with news about another life sciences board post that gives him a ringside chair to cheer on a lead player in the real-world evidence movement — one with very close ties to the FDA.

Aetion is reporting this morning that Gottlieb is joining their board, a group that includes Mohamad Makhzoumi, a general partner at New Enterprise Associates, where Gottlieb returned after stepping out of his role at the FDA 2 years after he started.

Gottlieb — one of the best connected execs in biopharma — knows this company well. As head of FDA he championed the use of real-world evidence to help guide drug developers and the agency in gaining greater efficiencies, which helped set up Aetion as a high-profile player in the game.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.